BioTech News Headlines - Yahoo! News

http://news.yahoo.com/biotech/ Get the latest Biotech news headlines from Yahoo! News. Find breaking Biotech news, including analysis and opinion on top Biotech stories, photos and more.en-USCopyright (c) 2012 Yahoo! Inc. All rights reservedWed, 08 Aug 2012 00:02:08 -04005http://news.yahoo.com/biotech/ http://l.yimg.com/a/i/us/nws/th/main_142c.gifTUESDAY, Aug. 7 (HealthDay News) -- A new genetic analysis of Jews from North Africa provides evidence that Middle Eastern Jews settled in the region during Classical Antiquity, married local populations and formed distinct populations that remained largely intact for more than 2,000 years.http://news.yahoo.com/genetic-research-sheds-light-jewish-diaspora-180446317.htmlWed, 08 Aug 2012 00:02:08 -0400HealthDaygenetic-research-sheds-light-jewish-diaspora-180446317TUESDAY, Aug. 7 (HealthDay News) -- Using human stem cells, scientists have developed methods to boost the production of red blood cells, according to a new study.http://news.yahoo.com/study-uses-stem-cells-boost-red-blood-cell-160404064.htmlWed, 08 Aug 2012 00:02:08 -0400HealthDaystudy-uses-stem-cells-boost-red-blood-cell-160404064<p><a href="http://news.yahoo.com/testers-fear-reality-genetically-modified-olympians-155257685--finance.html"><img src="http://l1.yimg.com/bt/api/res/1.2/k.GX5fbiSwUqw24JynRp7w--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2012-08-07T184830Z_1_CBRE8761G8X00_RTROPTP_2_UK-OLY-DOP-GENE-DAY11.JPG" width="130" height="86" alt="Johns Hopkins University scientists Se-Jun Lee (L) and Alexandra McPherron (R) look at a normal mouse and a genetically-engineered mouse (R) that is two to three times more muscular than the normal mouse in this undated handout photo" align="left" title="Johns Hopkins University scientists Se-Jun Lee (L) and Alexandra McPherron (R) look at a normal mouse and a genetically-engineered mouse (R) that is two to three times more muscular than the normal mouse in this undated handout photo" border="0" /></a>LONDON (Reuters) - There have been &quot;marathon mice&quot;, &quot;Schwarzenegger mice&quot; and dogs whose wasted muscles were repaired with injected substances that switch off key genes. It may not be long before we get the first genetically modified athlete. Some fear the use of gene therapy to improve athleticism is already a reality. But since sports authorities&#039; drug testing methods still lack the sophistication needed to pick up gene doping, its status remains unclear. ...</p><br clear="all"/>http://news.yahoo.com/testers-fear-reality-genetically-modified-olympians-155257685--finance.htmlTue, 07 Aug 2012 14:48:30 -0400Reuterstesters-fear-reality-genetically-modified-olympians-155257685--finance<p><a href="http://news.yahoo.com/testers-fear-reality-genetically-modified-olympians-155257685--finance.html"><img src="http://l1.yimg.com/bt/api/res/1.2/k.GX5fbiSwUqw24JynRp7w--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2012-08-07T184830Z_1_CBRE8761G8X00_RTROPTP_2_UK-OLY-DOP-GENE-DAY11.JPG" width="130" height="86" alt="Johns Hopkins University scientists Se-Jun Lee (L) and Alexandra McPherron (R) look at a normal mouse and a genetically-engineered mouse (R) that is two to three times more muscular than the normal mouse in this undated handout photo" align="left" title="Johns Hopkins University scientists Se-Jun Lee (L) and Alexandra McPherron (R) look at a normal mouse and a genetically-engineered mouse (R) that is two to three times more muscular than the normal mouse in this undated handout photo" border="0" /></a>LONDON (Reuters) - There have been &quot;marathon mice&quot;, &quot;Schwarzenegger mice&quot; and dogs whose wasted muscles were repaired with injected substances that switch off key genes. It may not be long before we get the first genetically modified athlete. Some fear the use of gene therapy to improve athleticism is already a reality. But since sports authorities&#039; drug testing methods still lack the sophistication needed to pick up gene doping, its status remains unclear. ...</p><br clear="all"/>* Animal experiments show gene therapy can boost performance * Gene doping likely to be dangerous and risky in humans * Tests can't detect it, so status of gene doping unclear LONDON, Aug 7 (Reuters) - There have been "marathon mice","Schwarzenegger mice" and dogs whose wasted muscles wererepaired with injected substances that switch off key genes. Itmay not be long before we get the first genetically modifiedathlete. Some fear the use of gene therapy to improve athleticism isalready a reality. ...http://news.yahoo.com/feature-testers-fear-reality-genetically-modified-olympians-155119055--finance.htmlTue, 07 Aug 2012 11:51:19 -0400Reutersfeature-testers-fear-reality-genetically-modified-olympians-155119055--financeNEW YORK (Reuters) - A new genetic analysis has reconstructed the history of North Africa's Jews, showing that these populations date to biblical-era Israel and are not largely the descendants of natives who converted to Judaism, scientists reported on Monday. The study also shows that these Jews form two distinct groups, one of which is more closely related than the other to their European counterparts, reflecting historical migrations. ...http://news.yahoo.com/genetic-study-offers-clues-history-north-africas-jews-211253960.htmlMon, 06 Aug 2012 17:12:53 -0400Reutersgenetic-study-offers-clues-history-north-africas-jews-211253960TEL AVIV (Reuters) - Pluristem Therapeutics said another patient suffering from bone marrow failure was saved using its placenta-based stem cell treatment. This is the second time in three months that a patient suffering from bone marrow failure was successfully treated with its PLX cells, the Israeli company said on Monday. The patient, a 54 year-old woman with lymphoma cancer, was treated with chemotherapy but her condition continued to deteriorate, necessitating a bone marrow transplant. The transplant, as well as alternate therapies, were not successful. ...http://news.yahoo.com/pluristem-stem-cells-save-second-patient-bone-marrow-070957565--finance.htmlMon, 06 Aug 2012 03:09:57 -0400Reuterspluristem-stem-cells-save-second-patient-bone-marrow-070957565--financeScientists have found new evidence for a theory about why some cancers return after they've seemingly been wiped out. Three studies in mice say tumors contain a pool of cancer stem cells that can multiply and seed the tumor's regrowth.http://news.yahoo.com/cancer-debate-tumors-fueled-stem-cells-172157763.htmlWed, 01 Aug 2012 13:03:51 -0400Associated Presscancer-debate-tumors-fueled-stem-cells-172157763WEDNESDAY, Aug. 1 (HealthDay News) -- While scientists hotly debate the existence of cancer stem cells, three related new studies, all conducted on mice, provide some supporting evidence.http://news.yahoo.com/evidence-grows-cancer-own-stem-cells-180411937.htmlWed, 01 Aug 2012 23:59:16 -0400HealthDayevidence-grows-cancer-own-stem-cells-180411937<p><a href="http://news.yahoo.com/stem-cells-blamed-cancer-growth-172102722.html"><img src="http://l.yimg.com/bt/api/res/1.2/rdMNY_2Wzxy2vERIqFDR6A--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/afp.com/photo_1343841604014-1-0.jpg" width="130" height="86" alt="Stem cells are viewed on a computer screen" align="left" title="Stem cells are viewed on a computer screen" border="0" /></a>Researchers presented evidence Wednesday for the existence of cancer stem cells, with three different studies seeking to end a decades-old scientific dispute about how tumours grow.</p><br clear="all"/>http://news.yahoo.com/stem-cells-blamed-cancer-growth-172102722.htmlWed, 01 Aug 2012 13:21:02 -0400AFPstem-cells-blamed-cancer-growth-172102722<p><a href="http://news.yahoo.com/stem-cells-blamed-cancer-growth-172102722.html"><img src="http://l.yimg.com/bt/api/res/1.2/rdMNY_2Wzxy2vERIqFDR6A--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/afp.com/photo_1343841604014-1-0.jpg" width="130" height="86" alt="Stem cells are viewed on a computer screen" align="left" title="Stem cells are viewed on a computer screen" border="0" /></a>Researchers presented evidence Wednesday for the existence of cancer stem cells, with three different studies seeking to end a decades-old scientific dispute about how tumours grow.</p><br clear="all"/>MONDAY, July 30 (HealthDay News) -- A new gene associated with a rare form of blindness from birth has been identified by researchers.http://news.yahoo.com/scientists-id-gene-linked-vision-loss-infants-160411860.htmlTue, 31 Jul 2012 00:13:08 -0400HealthDayscientists-id-gene-linked-vision-loss-infants-160411860SUNDAY, July 29 (HealthDay News) -- New gene mutations associated with the development of melanoma have been identified by scientists who conducted what is believed to be the largest DNA-sequencing study of the deadly disease to date.http://news.yahoo.com/scientists-uncover-gene-variation-linked-melanoma-180513963.htmlTue, 31 Jul 2012 00:13:08 -0400HealthDayscientists-uncover-gene-variation-linked-melanoma-180513963THURSDAY, July 26 (HealthDay News) -- Despite all the training, sweat, dedication and sacrifice that goes into becoming an Olympic competitor, these elite athletes also tend to have an advantage that average sports lovers lack: superior DNA. Just like eye color or a keen intellect, a constellation of the "right" genes can grace certain athletes with world-class speed, strength and endurance.http://news.yahoo.com/could-gene-doping-part-future-olympics-130409630.htmlSat, 28 Jul 2012 00:03:07 -0400HealthDaycould-gene-doping-part-future-olympics-130409630WEDNESDAY, July 25 (HealthDay News) -- Two years after he became the first child to receive a stem cell-supported trachea (windpipe) transplant, a 13-year-old boy is able to breathe normally, has grown about four inches taller, does not require any anti-rejection drugs and has returned to school.http://news.yahoo.com/teen-doing-well-2-years-stem-cell-windpipe-231123124.htmlFri, 27 Jul 2012 00:00:25 -0400HealthDayteen-doing-well-2-years-stem-cell-windpipe-231123124(Reuters) - Genetic Technologies Ltd said its lead cancer test BrevaGen has been cleared for sale in California, which it expects to be a large and significant market. The Nasdaq-listed shares of the company, which has operations in Australia and the United States, rose as much as 37 percent to $4.79 on Thursday morning, making it one of the top percentage gainers on the exchange. The genetic test maker said the Laboratory Field Services Unit of the California Department of Public Health had granted it a license to sell BrevaGen in the state. ...http://news.yahoo.com/genetic-technologies-gets-nod-sell-cancer-test-california-144917183--finance.htmlThu, 26 Jul 2012 10:49:17 -0400Reutersgenetic-technologies-gets-nod-sell-cancer-test-california-144917183--financeMONDAY, July 23 (HealthDay News) -- Scientists who used modified stem cells to rejuvenate damaged and aged heart cells from elderly heart failure patients say their research could one day lead to new treatments for the illness.http://news.yahoo.com/stem-cells-show-promise-heart-failure-treatment-200513557.htmlMon, 23 Jul 2012 23:51:19 -0400HealthDaystem-cells-show-promise-heart-failure-treatment-200513557TEL AVIV (Reuters) - A clinical trial of ALS patients conducted by BrainStorm Cell Therapeutics shows its adult stem cell therapy is well-tolerated, appears to be safe and does not present undue risk, according to an interim safety review. Moreover, in some patients signs of stabilization of the disease were detected. Israel-based BrainStorm is developing NurOwn for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. ...http://news.yahoo.com/israel-adult-stem-cell-trials-hope-als-patients-043152320--sector.htmlMon, 23 Jul 2012 00:31:52 -0400Reutersisrael-adult-stem-cell-trials-hope-als-patients-043152320--sectorWASHINGTON (Reuters) - Myriad Genetics Inc illegally patented acts of nature when it claimed ownership of two genes linked to cancer, the federal government told an appeals court on Friday. Lawyers from Myriad, as well as the American Civil Liberties Union and the U.S. Patent and Trademark Office appeared in the U.S. Court of Appeals for the Federal Circuit at the direction of the U.S. Supreme Court in order to examine the impact of Mayo v. Prometheus, the high court's March ruling that companies cannot patent observations about nature. ...http://news.yahoo.com/u-appeals-court-reconsiders-myriad-gene-patent-ruling-232531152--finance.htmlFri, 20 Jul 2012 19:25:31 -0400Reutersu-appeals-court-reconsiders-myriad-gene-patent-ruling-232531152--financeThe European Medicines Agency is recommending the first-ever approval of a gene therapy treatment in the EU, in a significant move for a type of treatment that has so far failed to deliver on its promise to cure diseases.http://news.yahoo.com/european-regulator-gene-therapy-treatment-ok-143146189.htmlFri, 20 Jul 2012 13:30:45 -0400Associated Presseuropean-regulator-gene-therapy-treatment-ok-143146189<p><a href="http://news.yahoo.com/european-regulators-back-first-gene-therapy-drug-123941621--sector.html"><img src="http://l.yimg.com/bt/api/res/1.2/Mozpf6Ea3wkDhmZijKLFlw--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2012-07-20T144845Z_1_CBRE86J155F00_RTROPTP_2_US-GENETHERAPY-EUROPE.JPG" width="130" height="86" alt="A gene therapy illustration courtesy of UniQure" align="left" title="A gene therapy illustration courtesy of UniQure" border="0" /></a>LONDON (Reuters) - European regulators have recommended approval of the Western world&#039;s first gene therapy drug -- after rejecting it on three previous occasions -- in a significant advance for the novel medical technology. More than 20 years since the first experiments with the ground-breaking method for fixing faulty genes, scientists and drug companies are still struggling to apply gene therapy in practice. ...</p><br clear="all"/>http://news.yahoo.com/european-regulators-back-first-gene-therapy-drug-123941621--sector.htmlFri, 20 Jul 2012 08:39:41 -0400Reuterseuropean-regulators-back-first-gene-therapy-drug-123941621--sector<p><a href="http://news.yahoo.com/european-regulators-back-first-gene-therapy-drug-123941621--sector.html"><img src="http://l.yimg.com/bt/api/res/1.2/Mozpf6Ea3wkDhmZijKLFlw--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2012-07-20T144845Z_1_CBRE86J155F00_RTROPTP_2_US-GENETHERAPY-EUROPE.JPG" width="130" height="86" alt="A gene therapy illustration courtesy of UniQure" align="left" title="A gene therapy illustration courtesy of UniQure" border="0" /></a>LONDON (Reuters) - European regulators have recommended approval of the Western world&#039;s first gene therapy drug -- after rejecting it on three previous occasions -- in a significant advance for the novel medical technology. More than 20 years since the first experiments with the ground-breaking method for fixing faulty genes, scientists and drug companies are still struggling to apply gene therapy in practice. ...</p><br clear="all"/><p><a href="http://news.yahoo.com/surge-biotech-deals-unlock-big-investor-profits-030018493--sector.html"><img src="http://l3.yimg.com/bt/api/res/1.2/P2jYjqMCwQKhvezBvfry.A--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2012-07-19T030018Z_1_CBRE86H11DG00_RTROPTP_2_HUMANGENOME.JPG" width="130" height="86" alt="The Human Genome Sciences Laboratories and Offices building is seen in Rockville, Maryland" align="left" title="The Human Genome Sciences Laboratories and Offices building is seen in Rockville, Maryland" border="0" /></a>NEW YORK (Reuters) - Large investors in U.S. biotech companies are likely to capture serious windfall profits as deal activity picks up in the sector. A Reuters analysis of investors&#039; average cost found that six U.S. biotech companies flagged as potential takeover targets could yield billions of dollars in profits for their major shareholders at current share prices. Ownership of these companies is dominated by a handful of institutional investors, such as Wellington Management, Fidelity Management &amp; Research, Capital Group Cos and T Rowe Price Associates. ...</p><br clear="all"/>http://news.yahoo.com/surge-biotech-deals-unlock-big-investor-profits-030018493--sector.htmlWed, 18 Jul 2012 23:00:18 -0400Reuterssurge-biotech-deals-unlock-big-investor-profits-030018493--sector<p><a href="http://news.yahoo.com/surge-biotech-deals-unlock-big-investor-profits-030018493--sector.html"><img src="http://l3.yimg.com/bt/api/res/1.2/P2jYjqMCwQKhvezBvfry.A--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2012-07-19T030018Z_1_CBRE86H11DG00_RTROPTP_2_HUMANGENOME.JPG" width="130" height="86" alt="The Human Genome Sciences Laboratories and Offices building is seen in Rockville, Maryland" align="left" title="The Human Genome Sciences Laboratories and Offices building is seen in Rockville, Maryland" border="0" /></a>NEW YORK (Reuters) - Large investors in U.S. biotech companies are likely to capture serious windfall profits as deal activity picks up in the sector. A Reuters analysis of investors&#039; average cost found that six U.S. biotech companies flagged as potential takeover targets could yield billions of dollars in profits for their major shareholders at current share prices. Ownership of these companies is dominated by a handful of institutional investors, such as Wellington Management, Fidelity Management &amp; Research, Capital Group Cos and T Rowe Price Associates. ...</p><br clear="all"/><p><a href="http://news.yahoo.com/dealtalk-surge-biotech-deals-unlock-big-investor-profits-110830044--sector.html"><img src="http://l.yimg.com/bt/api/res/1.2/izd3och5rxB6puIJI1fg3Q--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2012-07-18T215616Z_1_CBRE86H11DG00_RTROPTP_2_HUMANGENOME.JPG" width="130" height="86" alt="The Human Genome Sciences Laboratories and Offices building is seen in Rockville, Maryland" align="left" title="The Human Genome Sciences Laboratories and Offices building is seen in Rockville, Maryland" border="0" /></a>NEW YORK (Reuters) - Large investors in U.S. biotech companies are likely to capture serious windfall profits as deal activity picks up in the sector. A Reuters analysis of investors&#039; average cost found that six U.S. biotech companies flagged as potential takeover targets could yield billions of dollars in profits for their major shareholders at current share prices. Ownership of these companies is dominated by a handful of institutional investors, such as Wellington Management, Fidelity Management &amp; Research, Capital Group Cos and T Rowe Price Associates. ...</p><br clear="all"/>http://news.yahoo.com/dealtalk-surge-biotech-deals-unlock-big-investor-profits-110830044--sector.htmlWed, 18 Jul 2012 17:56:16 -0400Reutersdealtalk-surge-biotech-deals-unlock-big-investor-profits-110830044--sector<p><a href="http://news.yahoo.com/dealtalk-surge-biotech-deals-unlock-big-investor-profits-110830044--sector.html"><img src="http://l.yimg.com/bt/api/res/1.2/izd3och5rxB6puIJI1fg3Q--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2012-07-18T215616Z_1_CBRE86H11DG00_RTROPTP_2_HUMANGENOME.JPG" width="130" height="86" alt="The Human Genome Sciences Laboratories and Offices building is seen in Rockville, Maryland" align="left" title="The Human Genome Sciences Laboratories and Offices building is seen in Rockville, Maryland" border="0" /></a>NEW YORK (Reuters) - Large investors in U.S. biotech companies are likely to capture serious windfall profits as deal activity picks up in the sector. A Reuters analysis of investors&#039; average cost found that six U.S. biotech companies flagged as potential takeover targets could yield billions of dollars in profits for their major shareholders at current share prices. Ownership of these companies is dominated by a handful of institutional investors, such as Wellington Management, Fidelity Management &amp; Research, Capital Group Cos and T Rowe Price Associates. ...</p><br clear="all"/><p><a href="http://news.yahoo.com/gene-scans-show-colon-rectal-tumours-same-171815629.html"><img src="http://l1.yimg.com/bt/api/res/1.2/KfZAE1OJZhMLbHcEIyCC4Q--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/afp.com/photo_1342631830470-1-0.jpg" width="130" height="86" alt="National Institutes of Health Director Francis Collins" align="left" title="National Institutes of Health Director Francis Collins" border="0" /></a>The biggest genetic analysis of colon and rectal tumours show that these cancer types are almost indistinguishable, a finding that could improve treatment options, a study said on Wednesday.</p><br clear="all"/>http://news.yahoo.com/gene-scans-show-colon-rectal-tumours-same-171815629.htmlWed, 18 Jul 2012 13:18:15 -0400AFPgene-scans-show-colon-rectal-tumours-same-171815629<p><a href="http://news.yahoo.com/gene-scans-show-colon-rectal-tumours-same-171815629.html"><img src="http://l1.yimg.com/bt/api/res/1.2/KfZAE1OJZhMLbHcEIyCC4Q--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/afp.com/photo_1342631830470-1-0.jpg" width="130" height="86" alt="National Institutes of Health Director Francis Collins" align="left" title="National Institutes of Health Director Francis Collins" border="0" /></a>The biggest genetic analysis of colon and rectal tumours show that these cancer types are almost indistinguishable, a finding that could improve treatment options, a study said on Wednesday.</p><br clear="all"/><p><a href="http://news.yahoo.com/analysis-gsk-bolsters-medicine-chest-biotechnology-buy-161302865--finance.html"><img src="http://l3.yimg.com/bt/api/res/1.2/KgZnXn0AVAqHAyZlmK_3og--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2012-07-16T161302Z_1_CBRE86F191U00_RTROPTP_2_BRITAIN.JPG" width="130" height="86" alt="New Chief Executive of GlaxoSmithKline Witty poses for photographers outside the company headquarters in west London" align="left" title="New Chief Executive of GlaxoSmithKline Witty poses for photographers outside the company headquarters in west London" border="0" /></a>LONDON (Reuters) - GlaxoSmithKline chief executive Andrew Witty has an eye for a bargain. Despite paying a 99 percent premium for Human Genome Sciences, he is still getting the biotechnology company for less than half what it was worth 14 months ago. In exchange for his $3 billion cheque, which GSK can pay out of existing cash resources, Witty gets full control of a clutch of new medicines finally starting to flow from the decoding of human DNA. ...</p><br clear="all"/>http://news.yahoo.com/analysis-gsk-bolsters-medicine-chest-biotechnology-buy-161302865--finance.htmlMon, 16 Jul 2012 12:13:02 -0400Reutersanalysis-gsk-bolsters-medicine-chest-biotechnology-buy-161302865--finance<p><a href="http://news.yahoo.com/analysis-gsk-bolsters-medicine-chest-biotechnology-buy-161302865--finance.html"><img src="http://l3.yimg.com/bt/api/res/1.2/KgZnXn0AVAqHAyZlmK_3og--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2012-07-16T161302Z_1_CBRE86F191U00_RTROPTP_2_BRITAIN.JPG" width="130" height="86" alt="New Chief Executive of GlaxoSmithKline Witty poses for photographers outside the company headquarters in west London" align="left" title="New Chief Executive of GlaxoSmithKline Witty poses for photographers outside the company headquarters in west London" border="0" /></a>LONDON (Reuters) - GlaxoSmithKline chief executive Andrew Witty has an eye for a bargain. Despite paying a 99 percent premium for Human Genome Sciences, he is still getting the biotechnology company for less than half what it was worth 14 months ago. In exchange for his $3 billion cheque, which GSK can pay out of existing cash resources, Witty gets full control of a clutch of new medicines finally starting to flow from the decoding of human DNA. ...</p><br clear="all"/>COPENHAGEN (Reuters) - Danish biopharma firm Genmab has agreed to collaborate with Janssen Biotech to create and develop antibodies using its DuoBody technology platform and will receive an upfront payment of $3.5 million, Genmab said. Under the terms of the deal, Janssen will fully fund the research to be done at Genmab, and Genmab will potentially be entitled to milestone and license payments of up to about $175 million for each product as well as royalties on any commercialized products, Genmab said late on Thursday. ...http://news.yahoo.com/genmab-signs-antibody-research-deal-janssen-biotech-044529873--finance.htmlFri, 13 Jul 2012 00:45:29 -0400Reutersgenmab-signs-antibody-research-deal-janssen-biotech-044529873--financeTHURSDAY, July 12 (HealthDay News) -- A gene mutation linked to facial and skull abnormalities, as well as impairment of thinking skills, has been identified by scientists who confirmed their findings in zebrafish.http://news.yahoo.com/gene-mutation-linked-facial-skull-abnormalities-180407194.htmlThu, 12 Jul 2012 23:50:10 -0400HealthDaygene-mutation-linked-facial-skull-abnormalities-180407194

Source: http://rss.news.yahoo.com/rss/biotech

rondo morris claiborne mothers day gifts clippers lisa lampanelli lisa lampanelli bronx zoo